Sequential Skin Inc., a skin microbiome company developing non-invasive testing and data-driven solutions for the skin microbiome, has entered into a collaborative agreement with Johnson & Johnson Consumer Inc. to quantify skin health.
“This collaboration will give us the opportunity to improve upon our novel technologies at Sequential, to further understand how molecular changes on the skin may translate to skin and human health,” said Oliver Worsley, CEO and co-founder of Sequential Skin.
The joint efforts will focus on developing new methods for non-invasive genomic-based skin testing to help Sequential Skin add to its growing database of skin samples. According to the company, after having successfully launched the world’s first at-home skin microbiome test kit in 2019, it used this data to complement the B2B testing arm Sequential Bio, a microbiome testing company specifically for consumer products that supports their in vivo certification to "Maintain the Microbiome."
Notably, Sequential Bio won the Cosmetics & Toiletries Allē Award for most significant testing and claims method in the personal care industry in 2022. Its test for microbiome-friendly standards and certification was developed using next-generation sequencing of the collection of micro-organisms found on the skin, before and after product usage. It investigates microbial diversity and particular organisms known to play important roles in healthy skin.
Sequential Skin is supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, Corundum Systems Biology, and is a resident company of Johnson & Johnson Innovation – JLABS.